Skip to main content

Advertisement

Log in

Correlational study of vascular endothelial growth factor expression and microvessel density in primary malignant gastric lymphoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) in primary malignant gastric lymphoma were studied, and their correlation as well as its clinical significance was analyzed. Thirty-five patients diagnosed with primary malignant gastric lymphoma were enrolled in this study. VEGF expression in the tumor tissues was detected by immunohistochemistry. Microvessel density in tumors was counted with Weidner’s method and compared with MVD in normal tissues 5 cm away from tumor site. Collected data were analyzed statistically. Our results showed that VEGF expression and MVD in tumor tissues were higher than those in normal tissues, and the difference between these two groups was significant (P < 0.01). As VEGF expression was elevated, MVD was also increased in tumor tissues. Statistical analysis revealed that VEGF expression was positively correlated with MVD (r = 0.392, P < 0.05). VEGF was highly expressed in primary malignant gastric lymphoma and positively correlated with MVD. These results strongly suggest that anti-angiogenesis therapy investigated in gastric lymphoma is a prospective clinical trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Ferrarar N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4–25.

    Article  Google Scholar 

  2. Carron CP, Meyer DM, Pegg JA, Engleman VW, Nickols MA, Settle SL. A peptidomimetic antagonist of the integrin alpha (v) beta 3 inhibits leydig cell tumor growth and development of hypercalcemia of malignancy. Cancer Res. 1998;58:1930–5.

    PubMed  CAS  Google Scholar 

  3. Folkman J, D’Amore PA. Blood vessel formation: what is its molecular basis? Cell. 1996;87:1153–5.

    Article  PubMed  CAS  Google Scholar 

  4. Weidner N, Semple JP, Welch W, Folkman J. Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.

    Article  PubMed  CAS  Google Scholar 

  5. Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart M. Quantitative angiogenesis assessed by anti-PECAM antibodies: correlation with node metastasis and survival in breast cancer. Lancet. 1992;340:1120–4.

    Article  PubMed  CAS  Google Scholar 

  6. Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol. 1994;144:1188–94.

    PubMed  CAS  Google Scholar 

  7. Wakui S, Furusato M, Sasaki H, Akiyama A, Kinoshito I, Asano K. Tumor angiogenesis in prostatic carcinoma with and without bone metastasis: a morphometric study. J Pathol. 1992;168:257–62.

    Article  PubMed  CAS  Google Scholar 

  8. Macchiarini P, FontaniniGHardin MJ, Squartini F, Angeletti CA. Relation of neovascularization to metastasis of non-small cell lung carcinoma. Lancet. 1992;340:145–6.

    Article  PubMed  CAS  Google Scholar 

  9. Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol. 1993;24:220–6.

    Article  PubMed  CAS  Google Scholar 

  10. Smith-McCune KS, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 1994;54:804–8.

    Google Scholar 

  11. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29:252–60.

    Article  PubMed  CAS  Google Scholar 

  12. Herrmann R, Panahon AM, Barcos MP, Walsh D, Stutzman L. Gastrointestinal involvement in non-Hodgkin’s lymphoma. Cancer. 1980;46:215–22.

    Article  PubMed  CAS  Google Scholar 

  13. Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol. 2007;136:521–38.

    Article  PubMed  CAS  Google Scholar 

  14. Cogliatti SB, Schmid U, Schumacher U, Eckert F, Hansmann ML, Hedderich J. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology. 1991;101:1159–70.

    PubMed  CAS  Google Scholar 

  15. Buchler P, Reber HA, Buchler MW, Friess H, Hines OJ. VEGF influences the prognosis of panc reatic cancer. Ann Surg. 2002;236:728–49.

    Article  Google Scholar 

  16. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.

    Article  PubMed  CAS  Google Scholar 

  17. Ding G, Huang S, Chen XJ, Liu DH. The Relationship between VEGF in Experimental Rat and Tumor Angiogenesis Invasion and Metastasis. Pract J Cancer. 2010;25:551–3.

    Google Scholar 

  18. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401–10.

    Article  PubMed  CAS  Google Scholar 

  19. Yu MJ, Li HM. Advances in angiogenesis inhibitors of lymphoma. Journal of Pract Oncol. 2005;19:69–72.

    Google Scholar 

  20. Tang QL, Jiang XF, Yang KZ, Li HG, Liu WP, Peng ZL. Expression of VEGF and its significance in primary diffuse large B-cell lymphoma of the female genital system. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009;40:48–51.

    PubMed  CAS  Google Scholar 

  21. Ni Q, Wu ZS, Wu Q, Zhang SM, Zhou Q, Wang Y. Expression of ESM-1 and VEGF in non-Hodgkin lymphoma. Anhui Med Pharm J. 2004;9:104–5.

    Google Scholar 

  22. Filipits M, Jaeger U, Simonitsch I, Chizzali-Bonfadin C, Heinzl H, Pirker R. Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas. Clin Cancer Res. 2000;6:3417–23.

    PubMed  CAS  Google Scholar 

  23. Zeng CQ, Zheng Y, Huang LX, Li JD. Analysis of prognostic factors in lymph node-negative advanced gastric cancer patients. Zhonghua Wei Chang Wai Ke Za Zhi. 2011;14:111–3.

    PubMed  Google Scholar 

  24. Verheul HM, Hoekmank K, Joma AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist. 2000;5:45–50.

    Article  PubMed  CAS  Google Scholar 

  25. Ho CL, Sheu LF, Li CY. Immunohistochemical Expression of Basic Fibroblast Growth Factor, Vascular Endothelial Growth Factor, and Their Receptors in Stage IV Non-Hodgkin Lymphoma. Appl Immunohistochem Mol Morphol. 2002;10:316–21.

    Article  PubMed  CAS  Google Scholar 

  26. Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J. Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma. 2006;47:998–1005.

    Article  PubMed  CAS  Google Scholar 

  27. Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17:697–707.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Supported by Yunnan provincial department of education research funds (5Y04320).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zuo-Zhang Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xie, L., Shen, LD., Qing, C. et al. Correlational study of vascular endothelial growth factor expression and microvessel density in primary malignant gastric lymphoma. Med Oncol 29, 1711–1715 (2012). https://doi.org/10.1007/s12032-011-0008-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0008-8

Keywords

Navigation